Key takeaways
- TOFA is an experimental compound tested only in obese mice, not in humans.
- In the mouse study, it increased energy expenditure by up to 18 per cent without reducing food intake or physical activity.
- The mice lost fat without a significant drop in lean mass, and TOFA worked even better alongside semaglutide or tirzepatide.
- The compound has no approved human use, and three of the researchers have a financial stake in a company developing related drugs.
Most successful weight-loss drugs attack one side of the ledger: they make it easier to eat less. Ozempic, Wegovy, Mounjaro and Zepbound all lean on suppressing appetite. A new experimental compound out of the University of California, Berkeley works the other side of the equation entirely, at least in mice.
The compound is a TOFA, thankfully short for 5-tetradecyloxy-2-furoic acid. In a study published in Science Advances, obese mice given TOFA increased their energy expenditure by as much as 18 per cent. They did not eat less. They did not move more. Their body temperature barely changed. They simply burned more fuel doing the same things they were already doing.
“Body weight responds to two levers: taking in fewer calories, or spending more energy,” senior author Anders Näär told Berkeley’s research office. “GLP-1s work almost entirely on the first, so we went after the second.”
What the Mice Showed
The results were consistent across several measures. TOFA-treated mice lost body weight and fat mass. Their glucose control and insulin sensitivity improved. Triglycerides and markers linked to fatty liver disease fell. And in the body-composition measurements the researchers reported, lean mass held steady, with no statistically significant decline. That means no muscle loss.
That last point is doing a lot of work in how this study is being received. Rapid weight loss, including on GLP-1 drugs, can take muscle along with fat. A compound that strips fat while sparing lean tissue matters, particularly for older men, for whom preserving muscle is already a fight worth having on its own terms.
Why the mechanism is different
TOFA appears to work through two separate actions. To spare you a list lipid and enzymes, in plain terms, it turns down the body’s fat-production line while turning up the machinery that burns fuel.
Earlier drugs targeting ACC alone reached human trials before stalling, partly because they raised triglycerides. TOFA’s mouse data did not show that problem, which the researchers attribute to its added PPAR activity. It is one reason this mechanism is getting attention beyond the usual churn of mouse-study headlines, and part of the long-running search for an exercise pill that actually does something exercise does.
Where GLP-1 drugs fit in
TOFA is not being pitched as a rival to Ozempic or Mounjaro. In the mouse experiments, it produced stronger results when combined with semaglutide or tirzepatide than either did alone, and the researchers describe it as a possible complement to GLP-1 drugs rather than a replacement. That fits the fit-on-meds approach to preserving muscle during medically assisted weight loss, which has been gaining attention as more men use these drugs long term.
None of that means TOFA solves muscle loss in people currently on GLP-1 medication. Nobody has tested that combination outside a mouse cage, and it is not something to ask your doctor to approximate.
The Catch
TOFA has not been given to a single human patient. Successful mouse results get eye rolls from senior researchers due to the amount of times they stall. And this compound has not yet cleared the earliest human safety hurdles, let alone effectiveness ones.
Ed’s Note: There is also a commercial layer worth knowing before you get too excited. Senior author Anders Näär and two colleagues co-founded ReRx Therapeutics, a company developing drugs related to this work, and several authors hold pending patents covering TOFA’s therapeutic use. None of that undermines the science. It is a reason independent replication and controlled human trials matter more than usual here.
